Fact CheckerSign in

NCT07097415Completed

CGM-Assisted Community Management for Type 2 Diabetes

Continuous Glucose Monitoring-assisted Management for Type 2 Diabetes in Chinese Community Care: a Non-randomised Pragmatic Type 2 Effectiveness-Implementation Hybrid Study

Source: ClinicalTrials.gov · Last updated 23 Jul 2026

Brief summary (registry, in English)

This non-randomised, parallel-group pragmatic study used a type 2 effectiveness-implementation hybrid design to evaluate a continuous glucose monitoring (CGM)-assisted community management strategy for adults with type 2 diabetes in Yinzhou District, Ningbo, China. The study was conducted at two community health institutions that routinely provided chronic disease management services. Group assignment was not randomised and involved participant self-selection. A total of 599 participants were enrolled, including 292 participants in the CGM-assisted management group and 307 participants in the usual-care group. The intervention was a multicomponent CGM-assisted management strategy rather than the use of a CGM device alone. It included a CGM device with a mobile application and clinician-facing data platform, structured training for community providers, one-to-one patient education, a standardised workflow for interpreting glucose patterns and providing dietary, physical-activity, and medication-management advice, and three scheduled 14-day CGM wear periods at weeks 0, 8, and 16. After each wear period, participants returned for clinician review and management adjustment. Participants in the usual-care group continued routine community diabetes management, including self-monitoring of blood glucose. The primary effectiveness outcome was the between-group difference in HbA1c at 24 weeks. Secondary effectiveness outcomes included clinically meaningful HbA1c reductions and target attainment, fasting plasma glucose, body-mass index, lipid measures, behavioural changes, and changes in glucose-lowering medication management. CGM-derived glycaemic metrics were assessed descriptively within the intervention group across the three wear periods. Implementation outcomes were evaluated using the RE-AIM framework and included study-period reach, institutional and provider adoption, intervention delivery fidelity, participant completion, provider-perspective delivery cost, willingness to continue CGM use, participant satisfaction, and continuation of CGM-related services at the participating sites. The study aimed to assess both the effectiveness of CGM-assisted management and its implementation within routine Chinese community diabetes care.

Status (registry)
Completed
Study type
Interventional
Enrollment
599 (actual)
First submitted
4 Jul 2025
Start date
15 Nov 2024
Primary completion date
30 Nov 2025
Lead sponsor
Peking University
NCT number
NCT07097415

What you commit to

  • Study type: Interventional
  • Participants enrolled: 599
  • From 15 Nov 2024 to the primary completion date, 30 Nov 2025
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Lab values

  • Pregnancy.
    • Type 1 diabetes, latent autoimmune diabetes in adults, or secondary diabetes.
    • Current or previous use of glucose-affecting agents other than prescribed glucose-lowering medication, including systemic glucocorticoids.
    • Estimated glomerular filtration rate below 60 mL/min/1·73 m². ⑤Alanine aminotransferase or aspartate aminotransferase greater than three times the upper limit of normal.
    • Active malignancy. ⑦Inability to provide informed consent.

Who the study is looking for

  • Age 18 years or older. ②A diagnosis of type 2 diabetes recorded in the electronic medical record for at least 1 year before screening.
    • A stable glucose-lowering treatment regimen, defined as no change in medication class during the 3 months before screening.
    • Residence in Yinzhou District and enrolment in the district resident health-record system.
    • Ability to provide written informed consent. ⑥For enrolment into the CGM-assisted management group, ability to operate the CGM mobile application independently or with assistance from a caregiver.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Fuming Street Community Health Service Center
Coordinator of this site? Confirm its status
NingboChinaUnknown status
Qianhu Hospital
Coordinator of this site? Confirm its status
NingboChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.